TAK-828F
TAK-828F is a potent, selective, and orally available retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist (binding IC50=1.9 nM, reporter gene IC50=6.1 nM) . TAK-828F shows excellent RORγt isoforms selectivity (>5000-fold selectivity against human RORα and RORβ) [1].
Product Specifications
CAS Number
1854901-94-2
UNSPSC
12352005
Target
ROR
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/TAK-828F.html
Solubility
10 mM in DMSO
Smiles
CC1(C)C2=C(F)C=C(NC([C@@H]3N(C([C@@H]4C[C@H](CC(O)=O)C4)=O)CCC5=C3C=CC(OC)=N5)=O)C=C2CC1
Molecular Formula
C28H32FN3O5
Molecular Weight
509.57
References & Citations
[1]Kono M, et al. Discovery of [ cis-3- ({ (5 R) -5-[ (7-Fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl) carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6 (5 H) -yl}carbonyl) cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist. J Med Chem. 2018 Apr 12;61 (7) :2973-2988.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![Bosentan-d4 (4- (1,1-dimethylethyl) -N-[6- (2-hydroxyethoxy-d4) -5- (2-methoxyphenoxy) [2,2’-bipyrimidin]-4-yl]benzenesulfonamide)](https://cdn.genprice.uk/genprice/uk/genprice5.webp)
B2573-01 1 mg
Bosentan-d4 (4- (1,1-dimethylethyl) -N-[6- (2-hydroxyethoxy-d4) -5- (2-methoxyphenoxy) [2,2’-bipyrimidin]-4-yl]benzenesulfonamide)
Sign In for Pricing
View Details 
350439-01 50 µL
GNG2, NT (Guanine nucleotide-binding protein G (I) /G (S) /G (O) subunit gamma-2, G gamma-I)
Sign In for Pricing
View Details 350439-02 200 µL
GNG2, NT (Guanine nucleotide-binding protein G (I) /G (S) /G (O) subunit gamma-2, G gamma-I)
Sign In for Pricing
View Details